Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVA study: medication optimization for ADHD with methylphenidate titration
NL-OMON28746Recruiting
- Sponsor
- Innovatiefonds Zorgverzekeraars
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Innovatiefonds Zorgverzekeraars. Primary endpoints: Continuation of methylphenidate treatment after titration, Identification of non-response, placebo response, and insufficient clinical response and 3 more. Started May 2016; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON28746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28746.